Abstract YO36
Case summary
The frequency of BRAF mutation in non-small-cell lung cancer (NSCLC) is 1–2%. Some studies showed the patients with the mutation have poor outcomes to chemotherapy. Use of dabrafenib plus trametinib in BRAF V600E mutated NSCLC showed improvement in clinical outcomes of treatment-naïve and previously treated patients in phase II trials.
Pulmonary pleomorphic carcinoma (PPC) is a rare histologic subtype of NSCLC characterized by aggressive features with poor prognosis. Many of PPCs are reported to be resistant to chemotherapy and radiotherapy. Some types of targetable oncogenes have been detected in PPCs. However, the significance of BRAF mutation in PPC remains unclear.
Here we describe a patient with BRAF V600E mutated NSCLC with pleomorphic feature treated with BRAF and MEK inhibitor.
The patient is a 53-year-old woman. Chest CT scan revealed the mass invading the chest wall in the right middle lobe, hilar and mediastinal lymph node metastasis, and pleural dissemination. Biopsy from the primary tumor showed NSCLC-NOS. Gene analysis revealed the tumor was EGFR wild type, ALK/ROS-1 fusion negative, and PD-L1 TPS was 0%. Clinical stage was T4 N2 M1a, Stage IVA.
She received CDDP+GEM, Pemetrexed, and TS-1 sequentially, however, no response was obtained by these therapies. At the time of disease progression, right middle and lower lobe atelectasis was caused by the primary tumor and lymph nodes enlargement, and multiple bone metastasis emerged.
Re-biopsy was performed from the chest wall invasion site. The sample showed poor differentiated epithelial tumor cells and spindle cells suggesting pleomorphic feature and BRAF V600E was detected by next generation sequencing test.
Based on the result, we started dabrafenib plus trametinib therapy. The primary lesion and hilar lymph nodes rapidly shrunk resulting in atelectasis resolving on the chest X-ray in two weeks. The CT scan revealed dramatic tumor response in all metastatic legions. The response continued for about 10 months.
To best of our knowledge, few BRAF mutation positive NSCLC with pleomorphic feature cases have been reported. This case suggests that BRAF V600E mutation is also an important therapeutic target in PPC as much as in other histology.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
303P - Segmental mandibulectomy without reconstruction
Presenter: Yohei Morishita
Session: Poster display session
Resources:
Abstract
304P - Survival outcomes and survival predictors in recurrent and metastatic head and neck squamous cell cancer (R/M-HNSCC) patients treated with chemotherapy (CT) plus cetuximab as first-line therapy in a real-world study
Presenter: Filipa Pontes
Session: Poster display session
Resources:
Abstract
305P - A retrospective study to evaluate patient characteristics for recurrent head and neck cancer after definitive treatment
Presenter: Tetsuro Wakasugi
Session: Poster display session
Resources:
Abstract
306P - Efficacy and safety of apatinib in heavily pretreated metastatic adenocarcinoma of the head and neck
Presenter: Lin Gui
Session: Poster display session
Resources:
Abstract
307P - Lacrimal gland tumours: Clinical and epidemiological patterns in the United States
Presenter: Mahmoud KhalafAllah
Session: Poster display session
Resources:
Abstract
308P - Dental prophylaxis and 5-fluorouracil related oral mucositis in head and neck cancer patients: A population-based cohort study
Presenter: Yi-Fang Huang
Session: Poster display session
Resources:
Abstract
309P - Evaluation of a pharmacist-led opioid de-escalation (PLODE) program after chemoradiotherapy completion in head and neck cancer patients
Presenter: Ai Horinouchi
Session: Poster display session
Resources:
Abstract
310P - Laser and PDT for the oral leukoplakia
Presenter: Sadykov Rasul
Session: Poster display session
Resources:
Abstract
311P - Incidence of thyroid carcinoma in the Philippines: A retrospective study from a tertiary university hospital
Presenter: Priscilla Caguioa
Session: Poster display session
Resources:
Abstract
312P - Oral health disparities among privileged and underprivileged tribes of south India - A study on precancerous oral lesions prevalence
Presenter: Shanavas Palliyal
Session: Poster display session
Resources:
Abstract